Analysis of Headache Chronification With Imaging, Deep Phenotyping, and Proteomics
Part of paid clinical trials in Stanford, California.
- Sponsor
- Stanford University
- Study ID
- NCT03231241
- Status
- Recruiting
Conditions
- Chronic Daily Headache
- Chronic Migraine
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
Study is aimed at determining why some patients with episodic headache proceed to chronic daily or near daily headaches. The Investigators seek to discover differences in brain anatomy and function, composition of cerebrospinal fluid, blood products, genetics, and patient phenotypes that might help explain this process.
Key Dates
- Start date
- Dec 12, 2014
- Status verified
- Dec 2024
- Primary completion
- Aug 15, 2026
- Completion
- Sep 1, 2026
Study Design
- Enrollment
- 700 participants (estimated)
Arms
- Arm: Episodic HeadacheParticipants experiencing headache of any type more than twice per year but less than 15 days per month. No interventions
- Arm: Chronic HeadacheParticipants experiencing headache more than 15 days per month for at least three consecutive months. No interventions
- Arm: ControlParticipants reporting fewer than two headaches per year. No interventions
Primary Outcome Measure
Prediction of chronification of headache [ Time Frame: five years ]
Central Contacts
- Bharati Sanjanwala, M.Sc.650-721-2830
- Anthony Bet, B.S.650-683-5823
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94304 |
Find similar trials in Stanford, CA
By condition
By specialty
By research site
Related Studies
- Responding With Evidence and Access for Childhood HeadachesRecruiting · Children's Hospital Medical Center, Cincinnati · Birmingham, Alabama
- A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in AdultsPHASE2 · Recruiting · Ipsen · Birmingham, Alabama
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsPHASE3 · Recruiting · AbbVie · Huntsville, Alabama
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigrainePHASE3 · Recruiting · Merz Therapeutics GmbH · Chandler, Arizona